RxDoctor Payments Data

Emily Sankus

Family · Roseville, CANPI 1740566959

Payments from drug & device makers

$2,480in general payments, 2019–2025

Across 127 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$856
  • Lilly USA, LLC$372
  • AbbVie$334
  • AstraZeneca$202
  • Boehringer Ingelheim$146
  • Cardiovascular Systems Inc.$111
  • plus $459 from 13 others

What the payments were for

  • Food & beverage$2,480100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,480 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide107$126,978
OzempicSemaglutide61$75,645
JardianceEmpagliflozin45$69,031
EliquisApixaban71$53,753
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$52,638
DovatoDolutegravir Sodium/Lamivudine12$36,784
JanuviaSitagliptin Phosphate19$22,095
FarxigaDapagliflozin Propanediol20$21,015
WegovySemaglutide13$17,784
LinzessLinaclotide11$12,846
Atorvastatin Calcium323$4,122
Incruse ElliptaUmeclidinium Bromide11$3,341
Levothyroxine Sodium254$3,099
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,778
Losartan Potassium213$2,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Humulin 70-30$372$129,221120 claims
Novo NordiskOzempic, Wegovy$856$93,43074 claims
Boehringer IngelheimJardiance$146$69,03145 claims
GSKTrelegy Ellipta, Incruse Ellipta$69$55,97957 claims
PfizerEliquis$55$53,75371 claims
AstraZenecaFarxiga$202$21,01520 claims
AbbVieLinzess, Synthroid$334$13,71224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →